For ordering this report   For more information about this report  

 

2008 Drug Development Strategy Series, Analysis Edition 

 

Outline of the report

Points to be highlighted
Completely revised with new data in 2007 and information on overseas bases medium-sized pharmaceutical companies. The total number of page is 451, increased 65 pages from previous version.
Make full use of data from previous 5 "Drug Development Strategy Series", and analyze pharmaceuticals with active M & A, including total sales, sales depending on therapeutic classes and brands, R&D cost, emerging therapies, number of MRs.
Only one research paper in Japan that organize data for 15 years, including total sales, drug sales, profit & loss, organization, employee number, areas of research and development, emerging therapies, and registered drugs.

Seed Planning, Inc. has conducted original research and analyzed over 150 pharmaceutical companies including foreign-affiliated companies for 25 years, such as business concept, sales, profit, R&D cost, company and R&D organization, and emerging therapies. In this report, based on these analysis, 15-year's development especially R&D area according to companies and items is provided with easily viewable graphics.

In this report, information by October 2007 has been organized. This report contains wealth of information including new drug developers with drastic M&A and business reorganization and generic manufacturers not only in Japan but also in overseas. As this report provides overview of the whole industry including historical background, it is optimal as the basic information. In addition, electric list is available to modify or add information in your office.

Title of the report 2008 Drug Development Strategy Series, Analysis Edition 
Date of issue 16/05/08
Volume A4 / 451 pages
Price 170,000JPY
Produced by Seed Planning, Inc.
Note This report is written in Japanese.
Customers who need an English version:Please contact us.
Category Pharmaceutical products / compaines

Details of the report

Contents

Introduction
Research overview
Company list
Reference

  1. M&A, company split-up, how companies have been established
  2. R&D
    1. Focused research areas
    2. R&D cost
    3. R&D employee number
    4. Emerging therapies
    5. R&D Organization
  3. World-wide pharmaceutical companies and their Japanese offices
    1. Top 54 pharmaceutical companies in the world
    2. Top 300 prescription drugs in terms of sales in the world
    3. Ranking of pharmaceutical companies in the world in terms of total sales (2006-2007)
    4. Ranking of pharmaceutical companies in the world in terms of drug sales (2006-2007)
    5. Ranking of pharmaceutical companies in the world in terms of prescription drug sales (2006-2007)
    6. Ranking of pharmaceutical companies in the world in terms of R&D cost (2006-2007)
    7. Ranking of pharmaceutical companies in the world in terms of employee numbers (2006-2007)
    8. Pharmaceutical companies in the world by segment sales
    9. Pharmaceutical companies in the world by area sales
    10. Pharmaceutical companies in the world by R&D area
    11. Pharmaceutical companies in the world by total sales transition
    12. Pharmaceutical companies in the world by drug sales transition
    13. World-wide pharmaceutical companies and their Japanese offices
    14. Positioning of Japanese offices in world-wide pharmaceutical companies
    15. Establishment, M&A, and alteration of names for Japanese offices of foreign-affiliated companies
  4. Generic manufacturer
    1. Sales by generic manufacturer
    2. Total sales transition for top 10 companies for total sales
    3. Current profit transition for top 10 companies
    4. Drug sales transition and affiliated companies
    5. Ranking in terms of generics sales
    6. Ranking in terms of number of generics
    7. Sales and number of prescription drugs, proportion of generic sales
    8. Products
  5. Manufacturing Approval
    1. Registered drugs by therapeutic classes
    2. Registered drugs by companies
  6. Sales
  7. MR numbers and other employee numbers involved in medicine
  8. Company Overview
    1. Employee, capital, business hub, list of shareholders (136 companies)
    2. Change of shareholders
    3. Change of sales percentage distribution by section (139 companies)
    4. Transition of pharmaceutical business hub (137 companies)
    5. CEO
    6. Transition of current profit (129 companies)
    7. Transition of total sales and overseas sales (50 companies)
    8. List of export value (39 companies) (2006, 2007)
Market Research Report Electronics/IT Medical/biotechnology Health/nursing care/wellness

SPI-information is a website for SP Information selling marketing research reports produced in Japan and worldwide.